台湾地区肺癌中医体质类型和证候证型分布规律及与临床分期相关性研究
|
摘要
目的：一.探讨肺癌和中医体质的相关性；二.探讨肺癌中医证候(证型)的分布特点；三.探究肺癌中医体质和证候(证型)与肺癌临床分期(TNM)的相互关系,为今后中医临床建立起肺癌中医体质和证型整体结构的基本框架。
方法：将符合纳入标准的113例肺癌患者,对其进行中医体质分型,中医辨证分型及国际肺癌临床分期(TNM),用SPSS统计软件对数据进行统计,并进行交叉比较,以探明其内在的相关性
结果：
1.TNM分期分布情况
Ⅰ期3例(2%),Ⅱ期12例(11%),Ⅲ期43例(38%),Ⅳ期55例(49%)。
2.中医体质分布情况
气虚质36例(32%)>阴虚质19例(17%)>阳虚质16例(13%)>气郁质12例(11%)>痰湿质10例(9%)>平和质8例(7%)>血瘀质7例(6%)>湿热质3例(3%)>特禀质2例(2%)。
3.中医证型分布情况
气虚痰湿证16例(14%)；阴虚热毒证28例(25%)；气血瘀滞证22例(19%)气阴两虚证47例(42%)。
4肺癌中医体质与临床分期(TNM)的相互关系
Ⅰ期偏颇体质主要是阴虚质(33.3%)和痰湿质(33.3%)；Ⅱ期偏颇体质主要是气虚质(25%),其次是痰湿质(15.4%)、血瘀质(15.4%)、气郁质(15.4%)；Ⅲ期偏颇体质主要是气虚质(25.6%),其次是阴虚质(18.6%)、阳虚质(14%)、气郁质(11.6%)；Ⅳ期偏颇体质主要是气虚质(40%),其次是阳虚质(18.2%)、阴虚质(16.4%)、气郁质(9.1%)。
5.肺癌中医证型(证候)与临床分期(TNM)的相互关系
Ⅰ期Ⅱ期均以气虚痰湿证为主要证型,其次为气血瘀滞证；Ⅲ期以气阴两虚证及阴虚热毒证为主,其次为气血瘀滞证；Ⅳ期以气阴两虚证为主,其次为阴虚热毒证及气血瘀滞证。
6.肺癌中医体质与中医证型(证候)之间的相互关系
平和质、湿热质、特禀质与证型无相关,其余体质皆和证型有相关性。
结论：
1.肺癌患者TNM分期以晚期为多,Ⅲ、Ⅳ期患者共98例(87%)。
2.肺癌患者主要偏颇体质类型为气虚质,约占1/3(32%)；气虚质、阴虚质、阳虚质等虚性偏颇体质,约占2/3；气郁质、痰湿质、血瘀质、湿热质等实性偏颇体质占29%。
3.肺癌患者最常见的证型依次是：气阴两虚证(42%)>阴虚热毒证(25%)>气血瘀滞证(19%)>气虚痰湿证(14%)。
4.体质与分期
(1)ⅠⅡ期以阴虚质及气虚质等正虚体质为主,兼见邪实体质。
(2)ⅢⅣ期以气虚质、阳虚质、阴虚质等正虚体质为主且比重随病期逐渐上升,而邪实体质比例渐趋减少。
(3)气郁质在Ⅱ期Ⅲ期Ⅳ期是邪实体质的最主要类型
5.证型与分期
(1)ⅠⅡ期均以气虚痰湿证为主要证型。
(2)ⅢⅣ期均以气阴两虚证为主要证型。
(3)气血瘀滞证贯穿各期,在Ⅱ期Ⅲ期Ⅳ期均有一定比例。
6.体质与证型
平和质、湿热质及特禀质与肺癌临床证型无关；气虚质和气阴两虚证、阳虚质和气阴两虚证、阴虚质和阴虚热毒证、痰湿质和气虚痰湿证、血瘀质和气血瘀滞证、气郁质和气血瘀滞证相关。
Objective:1. To explore the correlation between the lung cancer and TCM constitution;2. To explore the factors influencing the distribution of TCM symptoms; To investigate the correlation between TCM constitutions/symptoms and the TNM stages for lung cancer. This thesis is aimed to establish a theoretical frame for clinical analysis of TCM constitutions/symptoms in patients with lung cancer.
Methodology:113eligible patients with lung cancer were stratified according to TCM constitutions, TCM symptoms, and the TNM stages for lung cancer. The statistical data derived from SPSS software were also cross-compared to identify the internal correlation.
Result:
1. Distribution of TNM stages
Stage I:3patients (2%); Stage II:12patients (11%); Stage Ⅲ:43patients (38%); Stage IV:55patients (49%)
2. Distribution of TCM constitutions
Qi Deficiency constitution:36patients (32%)> Yin Deficiency constitution:19patients (17%)> Yang Deficiency constitution:16patients (13%)> Qi depression constitution:12patients (11%)> Phlegm-dampness constitution:10patients (9%)> yin-yang harmony constitution:8patients (7%)> Blood stasis constitution:7patients (6%)> Dampness-heat constitution:3patients (3%)> allergic constitution:
2patients (2%).
3. Distribution of TCM symptoms
Deficiency of qi and phlegm and dampness syndrome:16patients (14%); deficiency of yin and excessive heat syndrome:28patients (25%); Qi stagnation and blood stasis syndrome:22patients (19%); Qi-Yin deficiency syndrome:47patients (42%).
4. Correlation between TCM constitutions and TNM stages in patients with lung cancer
Stage Ⅰ:Yin Deficiency constitution (33.3%) and Phlegm-dampness constitution (33.3%); Stage Ⅱ:Qi Deficiency constitution (25%), followed by Phlegm-dampness constitution (15.4%), Blood stasis constitution (15.4%), and Qi depression constitution (15.4%); Stage III:Qi Deficiency constitution (25.6%), followed by Yin Deficiency constitution (18.6%), Yang Deficiency constitution (14%), and Qi depression constitution (11.6%); Stage IV:Qi Deficiency constitution (40%), followed by Yang Deficiency constitution (18.2%), Yin Deficiency constitution (16.4%), and Qi depression constitution (9.1%).
5. Correlation between TCM symptoms and TNM stages in patients with lung cancer
Stages I and II:Deficiency of qi and phlegm and dampness syndrome, followed by Qi stagnation and blood stasis syndrome; Stage III:Qi-Yin deficiency syndrome and deficiency of yin and excessive heat syndrome, followed by Qi stagnation and blood stasis syndrome; Stage IV: Qi-Yin deficiency syndrome, followed by deficiency of yin and excessive heat syndrome and Qi stagnation and blood stasis syndrome.
6. Correlation between TCM constitutions and TCM symptoms in patients with lung cancer
TCM constitutions and TCM symptoms are correlated in all parameters other than yin-yang harmony constitution, Dampness-heat constitution, and allergic constitution.
Conclusion:
1. A majority of patients with lung cancer presented with advanced stages, i.e. a total of98patients in Stages Ⅲ and Ⅳ (87%).
2. A majority of patients with lung cancer presented with Qi Deficiency constitution (1/3,32%); Qi Deficiency constitution, Yin Deficiency constitution, and Yang Deficiency constitution (2/3); Qi Deficiency constitution, Phlegm-dampness constitution, Blood stasis constitution, and Dampness-heat constitution (29%).
3. Most common TCM symptoms in patients with lung cancer include (in the descending order):Qi-Yin deficiency syndrome (42%)> deficiency of yin and excessive heat syndrome (25%)> Qi stagnation and blood stasis syndrome (19%)>(Deficiency of qi and phlegm and dampness syndrome)(14%).
4. Stages and TCM constitutions
(1) Stages Ⅰ and Ⅱ:Dominant in Yin Deficiency constitution, and Qi Deficiency constitution, followed by excessive pathogen constitution.
(2) Stages Ⅲ and Ⅳ:Dominant in Qi Deficiency constitution, Yang Deficiency constitution, and Yin Deficiency constitution, the proportion of which increased with disease severity (stages) while the proportion of excessive pathogen constitutions decreased.
(3) Stages Ⅱ, Ⅲ, and Ⅳ:Qi depression constitution constituted a majority of excessive pathogen constitution.
5. Stages and TCM symptoms
(1) Stages Ⅰ and Ⅱ:Dominant in Deficiency of qi and phlegm and dampness syndrome
(2) Stages Ⅲ and Ⅳ:Dominant in Qi-Yin deficiency syndrome
(3) Qi stagnation and blood stasis syndrome was observed across all the stages, with a higher proportion in Stages Ⅱ, Ⅲ, and Ⅳ.
6. TCM constitutions and TCM symptoms
Yin-yang harmony constitution, Dampness-heat constitution and allergic constitution was not correlated to TCM symptoms while Qi Deficiency constitution and Qi-Yin deficiency syndrome, Yang Deficiency constitution and Qi-Yin deficiency syndrome, Yin Deficiency constitution and deficiency of yin and excessive heat syndrome, Phlegm-dampness constitution and Deficiency of qi and phlegm and dampness syndrome, Blood stasis constitution and Qi stagnation and blood stasis syndrome, Qi depression constitution and Qi stagnation and blood stasis syndrome were correlated.
方法：将符合纳入标准的113例肺癌患者,对其进行中医体质分型,中医辨证分型及国际肺癌临床分期(TNM),用SPSS统计软件对数据进行统计,并进行交叉比较,以探明其内在的相关性
结果：
1.TNM分期分布情况
Ⅰ期3例(2%),Ⅱ期12例(11%),Ⅲ期43例(38%),Ⅳ期55例(49%)。
2.中医体质分布情况
气虚质36例(32%)>阴虚质19例(17%)>阳虚质16例(13%)>气郁质12例(11%)>痰湿质10例(9%)>平和质8例(7%)>血瘀质7例(6%)>湿热质3例(3%)>特禀质2例(2%)。
3.中医证型分布情况
气虚痰湿证16例(14%)；阴虚热毒证28例(25%)；气血瘀滞证22例(19%)气阴两虚证47例(42%)。
4肺癌中医体质与临床分期(TNM)的相互关系
Ⅰ期偏颇体质主要是阴虚质(33.3%)和痰湿质(33.3%)；Ⅱ期偏颇体质主要是气虚质(25%),其次是痰湿质(15.4%)、血瘀质(15.4%)、气郁质(15.4%)；Ⅲ期偏颇体质主要是气虚质(25.6%),其次是阴虚质(18.6%)、阳虚质(14%)、气郁质(11.6%)；Ⅳ期偏颇体质主要是气虚质(40%),其次是阳虚质(18.2%)、阴虚质(16.4%)、气郁质(9.1%)。
5.肺癌中医证型(证候)与临床分期(TNM)的相互关系
Ⅰ期Ⅱ期均以气虚痰湿证为主要证型,其次为气血瘀滞证；Ⅲ期以气阴两虚证及阴虚热毒证为主,其次为气血瘀滞证；Ⅳ期以气阴两虚证为主,其次为阴虚热毒证及气血瘀滞证。
6.肺癌中医体质与中医证型(证候)之间的相互关系
平和质、湿热质、特禀质与证型无相关,其余体质皆和证型有相关性。
结论：
1.肺癌患者TNM分期以晚期为多,Ⅲ、Ⅳ期患者共98例(87%)。
2.肺癌患者主要偏颇体质类型为气虚质,约占1/3(32%)；气虚质、阴虚质、阳虚质等虚性偏颇体质,约占2/3；气郁质、痰湿质、血瘀质、湿热质等实性偏颇体质占29%。
3.肺癌患者最常见的证型依次是：气阴两虚证(42%)>阴虚热毒证(25%)>气血瘀滞证(19%)>气虚痰湿证(14%)。
4.体质与分期
(1)ⅠⅡ期以阴虚质及气虚质等正虚体质为主,兼见邪实体质。
(2)ⅢⅣ期以气虚质、阳虚质、阴虚质等正虚体质为主且比重随病期逐渐上升,而邪实体质比例渐趋减少。
(3)气郁质在Ⅱ期Ⅲ期Ⅳ期是邪实体质的最主要类型
5.证型与分期
(1)ⅠⅡ期均以气虚痰湿证为主要证型。
(2)ⅢⅣ期均以气阴两虚证为主要证型。
(3)气血瘀滞证贯穿各期,在Ⅱ期Ⅲ期Ⅳ期均有一定比例。
6.体质与证型
平和质、湿热质及特禀质与肺癌临床证型无关；气虚质和气阴两虚证、阳虚质和气阴两虚证、阴虚质和阴虚热毒证、痰湿质和气虚痰湿证、血瘀质和气血瘀滞证、气郁质和气血瘀滞证相关。
Objective:1. To explore the correlation between the lung cancer and TCM constitution;2. To explore the factors influencing the distribution of TCM symptoms; To investigate the correlation between TCM constitutions/symptoms and the TNM stages for lung cancer. This thesis is aimed to establish a theoretical frame for clinical analysis of TCM constitutions/symptoms in patients with lung cancer.
Methodology:113eligible patients with lung cancer were stratified according to TCM constitutions, TCM symptoms, and the TNM stages for lung cancer. The statistical data derived from SPSS software were also cross-compared to identify the internal correlation.
Result:
1. Distribution of TNM stages
Stage I:3patients (2%); Stage II:12patients (11%); Stage Ⅲ:43patients (38%); Stage IV:55patients (49%)
2. Distribution of TCM constitutions
Qi Deficiency constitution:36patients (32%)> Yin Deficiency constitution:19patients (17%)> Yang Deficiency constitution:16patients (13%)> Qi depression constitution:12patients (11%)> Phlegm-dampness constitution:10patients (9%)> yin-yang harmony constitution:8patients (7%)> Blood stasis constitution:7patients (6%)> Dampness-heat constitution:3patients (3%)> allergic constitution:
2patients (2%).
3. Distribution of TCM symptoms
Deficiency of qi and phlegm and dampness syndrome:16patients (14%); deficiency of yin and excessive heat syndrome:28patients (25%); Qi stagnation and blood stasis syndrome:22patients (19%); Qi-Yin deficiency syndrome:47patients (42%).
4. Correlation between TCM constitutions and TNM stages in patients with lung cancer
Stage Ⅰ:Yin Deficiency constitution (33.3%) and Phlegm-dampness constitution (33.3%); Stage Ⅱ:Qi Deficiency constitution (25%), followed by Phlegm-dampness constitution (15.4%), Blood stasis constitution (15.4%), and Qi depression constitution (15.4%); Stage III:Qi Deficiency constitution (25.6%), followed by Yin Deficiency constitution (18.6%), Yang Deficiency constitution (14%), and Qi depression constitution (11.6%); Stage IV:Qi Deficiency constitution (40%), followed by Yang Deficiency constitution (18.2%), Yin Deficiency constitution (16.4%), and Qi depression constitution (9.1%).
5. Correlation between TCM symptoms and TNM stages in patients with lung cancer
Stages I and II:Deficiency of qi and phlegm and dampness syndrome, followed by Qi stagnation and blood stasis syndrome; Stage III:Qi-Yin deficiency syndrome and deficiency of yin and excessive heat syndrome, followed by Qi stagnation and blood stasis syndrome; Stage IV: Qi-Yin deficiency syndrome, followed by deficiency of yin and excessive heat syndrome and Qi stagnation and blood stasis syndrome.
6. Correlation between TCM constitutions and TCM symptoms in patients with lung cancer
TCM constitutions and TCM symptoms are correlated in all parameters other than yin-yang harmony constitution, Dampness-heat constitution, and allergic constitution.
Conclusion:
1. A majority of patients with lung cancer presented with advanced stages, i.e. a total of98patients in Stages Ⅲ and Ⅳ (87%).
2. A majority of patients with lung cancer presented with Qi Deficiency constitution (1/3,32%); Qi Deficiency constitution, Yin Deficiency constitution, and Yang Deficiency constitution (2/3); Qi Deficiency constitution, Phlegm-dampness constitution, Blood stasis constitution, and Dampness-heat constitution (29%).
3. Most common TCM symptoms in patients with lung cancer include (in the descending order):Qi-Yin deficiency syndrome (42%)> deficiency of yin and excessive heat syndrome (25%)> Qi stagnation and blood stasis syndrome (19%)>(Deficiency of qi and phlegm and dampness syndrome)(14%).
4. Stages and TCM constitutions
(1) Stages Ⅰ and Ⅱ:Dominant in Yin Deficiency constitution, and Qi Deficiency constitution, followed by excessive pathogen constitution.
(2) Stages Ⅲ and Ⅳ:Dominant in Qi Deficiency constitution, Yang Deficiency constitution, and Yin Deficiency constitution, the proportion of which increased with disease severity (stages) while the proportion of excessive pathogen constitutions decreased.
(3) Stages Ⅱ, Ⅲ, and Ⅳ:Qi depression constitution constituted a majority of excessive pathogen constitution.
5. Stages and TCM symptoms
(1) Stages Ⅰ and Ⅱ:Dominant in Deficiency of qi and phlegm and dampness syndrome
(2) Stages Ⅲ and Ⅳ:Dominant in Qi-Yin deficiency syndrome
(3) Qi stagnation and blood stasis syndrome was observed across all the stages, with a higher proportion in Stages Ⅱ, Ⅲ, and Ⅳ.
6. TCM constitutions and TCM symptoms
Yin-yang harmony constitution, Dampness-heat constitution and allergic constitution was not correlated to TCM symptoms while Qi Deficiency constitution and Qi-Yin deficiency syndrome, Yang Deficiency constitution and Qi-Yin deficiency syndrome, Yin Deficiency constitution and deficiency of yin and excessive heat syndrome, Phlegm-dampness constitution and Deficiency of qi and phlegm and dampness syndrome, Blood stasis constitution and Qi stagnation and blood stasis syndrome, Qi depression constitution and Qi stagnation and blood stasis syndrome were correlated.
引文
[1]Doll R, Hill AB. Mortality in relation to smoking:Ten years of observations of British doctors. Br Med J 1964:1399-1410.
[2]Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in brochiogenus carcinoma. A study of six hundred and eighty four proved cases. JAMA 1950; 143:328-336.
[3]Miller BA,Ries LAQHankey BF,et al.(1993)SEER Cancer Statistics Review 1973-1990.Bethesda, MD:NIH Pub.No.93-2789.
[4]Doll R,Gray R,Hafner B,et al.(1980)Mortality in relation to smoking:22 years'observations on female British doctors.Br Med J 1,967-971.
[5]Walter SD,Kubik A,Parkin DM,et al.(1992)The natural history of lung cancer estimated from the result of a randomized trial of screening.Cancer Causes and Control,3,115-123.
[6]Garfinkel L,Stellman SD(1988)Smoking and lung cancer in women:findings in a prospective study. Cancer Res 48,6951-6955.
[7]Kaufman DW,Palmer JR,Rosenberg L,et al.(1989)Tar content of cigarettes in relation to lung cancer.Am J Epidemiol,129,703-711.
[8]Kubik A,ReissigovaJ(1990)Nepriznivyvyvojumrtnosti na plicnirakovinu vCesk6republice.Cas.Lek.ces., 129,217-1223.
[9]Davila DG, Williams DE(1993)The etiology of lung cancer.Mayo Clin.Proc.,68,170-182.
[10]Nilson R(2001)Environmental tobacco smoke revisited:the reliability of the data used for risk assessment.Risk Anal,Aug;21 (4),737-760.
[11]Trichopolous D,Kalandini A,Sparros L,et al.(1984)Passive smoking and lung cancer.Lancet,1,684.
[12]Environmental Protection Agency:Respiratory health effects of passive smoking:lung cancer and other disorders.Washington:Epa,1992.
[13]Samet JM(ed.)Epidemiology of lung cancer.New York:Marcel Dekker,Inc.1994.P.544.
[14]Kabat GC. Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Lung Cancer 1996; 15:1-20.
[15]Du YX, Cha Q, Chen XW, et al. An epidemiological study of risk factors for lung cancer in Guangzhou, China. Lung Cancer 1996; 14:S9-37.
[16]Shen XB, Wang GX, Huang YZ, et al. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer 1996; 14:S107-S112.
[17]Kabat GC, Wynder EL. Lung cancer in nonsmokers. Cancer 1984; 53:1214-1221.
[18]Luh KT, Chang DB. Primary lung cancer in Taiwan. J Formosan Med Assoc 1992; 91:S1-S7.
[19]王志瑾.肺癌流行病学[J]肿瘤防治杂志,2002,9(1)：1-5.
[20]Ko YC,Cheng LS,Lee CH,et al.Chinese food cooking and lung cancer in women nonsmokers[J].Am J Epidemiol,2000,151 (2):140-147.
[21]Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci1979;330:473-490.
[22]Rugo HS. Occupational cancer. In:Current Occupational& Environmental Medicine,4th Ed. LaDou J (ed).NewYork:McGraw-Hill,2007, p224-261.
[23]Samet JM(1989)Radon and lung cancer.J Natl Cancer Inst 81,745-757.
[24]Garfinkel L(1981)Time trends in lung cancer mortality among non-smokers and a note on passive smoking.J Natl Cancer Inst 66,1061-1066.
[25]Field RW,Krewski D,Lubin JH,et al.An overview of the North American residential radon and lungcancer case-control studies.J Toxicol Environ Health A.2006 Apr;69(7):599-631.
[26]Lubin JH,Boice JD(1989)Estimating Rn-induced lung cancer in the United States.Health Phys 57,417-427.
[27]Agudo A, Esteve MG, Pallares C, et al. Vegetable and fruit intake and the risk of lung cancer in women in Barcelona, Spain. Eur J Cancer 1997; 33:1256-1261.
[28]Alavanja MCR, Field RW, Sinha R, et al. Lung cancer risk and red meat consumption among Iowa women. Lung Cancer 2001; 34:37-46.
[29]Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48:7279-7284.
[30]Voorrips LE, Goldbohm RA, Brants HA, et al. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:357-365.
[31]Ko YC, Lee CH, Chen MJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997; 26:24-31.
[32]Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48:7279-7284.
[33]Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001; 22:593-597.
[34]Rajaee-Behbahani N, Schmezer P, Risch A, et al. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer 2001; 95:86-91.
[35]Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61:1354-1357.
[36]Qingyi W, Lie C, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk:a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772.
[37]Cheng L, Spitz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer:a case-control analysis. Carcinogenesis 2000; 21:1527-1530.
[38]Ide F, Iida N, Nakatsuru Y, et al. Mice deficient in the nucleotide excision repair gene XPA have elevated sensitivity to benzo[a]pyrene induction of lung tumors. Carcinogenesis 2000; 21:1263-1265.
[39]Zienolddiny S, Ryberg D, Gazdar AF, et al. DNA mismatch binding in human lung tumor cell lines. Lung Cancer 1999; 26:15-25.
[40]Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987; 40:604-609.
[41]Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44:833-839.
[42]Freedman Da,Navidi WC(1990)Ex-smokers and the multistage model for lung cancer.Epidemiology, 1,21-29.
[43]Bernard W.Stewart,Paul Kleihues,edit.World Cancer Report.IARC Press.Lyon 2003:185.
[44]黄信孚,林木耀主编.现代肿瘤学诊疗手册.北京：北京医科大学中国协和医科大学联合出版社,1995.323.
[45]马文江,周建英,王雪芬等.原发性肺类癌42例临床分析[J].浙江医学,2003,25(7)：415-417.
[46]Waller DA.Surgery for non-small cell lung cancer-new trends.Lung Cancer,2001,34(Suppl 2):S133-136.
[47]李佩文主编.肺癌综合诊疗学.中国中医药出版社,2001：303-304.
[48]刘嘉湘,施志明,徐振华等.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J]中医杂志,1995：36(3)：155-158
[49]李际强.刘伟胜攻毒法治疗肺癌经验简介[J].辽宁中医杂志,2009：36(3)：340-341
[50]郑红刚,花宝金,朴炳奎.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007；26(5)：273-275.
[51]张霆.从伏气学说探讨肺癌之病因病机7J2.中医研究,2007；20(3)：5-7.
[52]赵景芳.七情与癌的发生.江苏中医药,2990,11(11)：42
[53]匡调元.论辨证与辨体质[J].中国中医基础医学杂志,2002,8(2)：1.
[54]匡调元.中医体质病理学[M],上海；上海科学普及出版社,1996
[55]王琦.中医体质学[M].北京：人民卫生出版社,2005：2-85
[56]王琦.中医体质学说的研究现状与展望[J].山东中医学院学报,1994,18(2)：74.
[57]邓海滨,王中奇.徐振哗辨治肺癌经验[J].四川中医,2002；20：1-2.
[58]刘振东,吴林生,周维顺.治疗肺癌经验[J].浙江中医学院学报,2004；28：39-40
[59]马纯正,牛喜伟.中医辨证治疗晚期非小细胞肺癌62例[J].中医杂志,2003,44(8)：6
[60]王维.原发性支气管肺癌的辨证论治[J].中华实用中西医杂志,2005,14(4)：399-401
[61]陈四清,周仲瑛.原发性支气管肺癌辨证分型探讨[J].新中医,2002；34(11)：6-8
[62]贾立群,朱世杰.现代名中医肿瘤科绝技[M].北京：(周岱翰老中医治肺癌经验)科学技术文献出版社,2002
[63]赵炜.李佩文治疗肺癌的经验[J].北京中医杂志,2002,21(6)：329-330
[64]刘静冰.章永红教授辨治肿癌经验探要[J].实用中医内科杂志,2002,16(3)：124-125
[65]曹阳,李忠,辨证治疗晚期非小细胞肺癌31例[J].北京中医药大学学报,2000,23(2)：66
[66]崔同建.中西医结合治疗非小细胞肺癌75例疗效分析[J].福建中医药,2002,33(2)：7-8
[67]陈国荣.中西医结合治疗非小细胞肺癌疗效观察[J].中国中西医结合杂志,1999,19(10)：620-621
[68]王三虎.肺癌急症辨证论治.中国中西医结合急救杂志,2006,13(5)：314
[69]夏黎明,林起铨,吴飞雪等.中医药治疗原发性肺癌临床疗效探析[J].中国中医基础医学杂志,2001,7(8)：52-54
[70]苗文红.中医辨证治疗肺癌89例报告[J].陕西肿瘤医学,2001,9(：1)59
[71]李际强,罗翌,徐凯.刘伟胜教授治疗肺癌经验介绍.新中医,2007,39(3)：99-100
[72]夏绍军.中医药与肿瘤的免疫调节概述[J].中医药临床杂志,2004,16(4)：288-289
[73]刘嘉湘.滋阴生津温阳法治疗晚期原发性肺腺癌的临床观察.中医杂志,1995,3：155-158
[74]李东方,中医辨证治疗晚期非小细胞肺癌32例临床观察[J].四川中医,2003,21(1)：33-34
[75]王永炎.中医内科学.第6版,上海科学技术出版社,1997,94-95
[76]王义明.扶正养阴法在治疗支气管肺癌中的应用[J].辽宁中医杂志,1985,9(8)：25.
[77]韩照予,马显振,张耀勇.穴位注射治疗肝癌介入术后呃逆33例[J].中国中西医结合杂志,2001,21(1)：50
[78]李佩文,张代钊.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995,36(2)：87-88.
[79]扬爱光,王兴双.安肺膏外贴治疗肺癌.中医外治杂志,996,(2)：31
[80]朴柄奎.肺瘤平膏治疗晚期原发性肺癌临床观察[J].中医杂志,1991,32(4)：21.
[81]李勇,徐凯.正气化癌膏治疗癌性疼痛30例疗效观察.新中医,2005,40(9)36-37
[82]孙大兴,裘维焰.肺康方治疗中晚期非小细胞肺癌疗效分析.中医药学报,2002；30(2)：49-50.
[83]张亚声.中药外敷治疗恶性胸水50例[J].中医杂志,1993,34(9)：545.
[84]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验.四川中医,2005,23(7)：5-6
[85]赵镜平.艾迪注射液治疗老年晚期非小细胞肺癌疗效观察.药物与临床,2010,48(2)：49
[86]张肖晗.针药并用治疗肿瘤化疗后骨髓抑制临床观察.中华实用中西医杂志.2007,20(6)：502-503
[87]谭兴超.复方苦参注射液治疗晚期非小细胞肺癌临床观察.当代医学,2010,16(3)：65
[88]刘家祥,韩平,王博文.中药配合化疗肺癌30例疗效观察[J],江西中医,2001,22(10)：25-26
[89]李柳宁,刘伟胜.千金苇茎汤加味在肺癌围放疗期的临床应用.辽宁中医杂志,2006,33(12)：1599
[90]陈乃杰,中医辨证配合化疗治疗晚期非小细胞肺癌41例[J].浙江中西医结合杂志,2000,10(1)：6-7
[91]李斯文.康莱特联合化疗治疗非小细胞肺癌的临床研究.肿瘤杂志,2002,22(1)：84
[92]马建青.康艾注射液对晚期肺癌放疗的协助作用.中国中药杂志,2006,31(18)：1556-1558
[93]郝迎旭,崔惠娟,蔡光蓉,等.扶正增效方对肺癌放射作用的研究[J].中医杂志,1997,38(2)：84-85
[94]崔红梅,毋子亭.健脾益肾法合化疗治疗中晚期肺癌疗效观察.辽宁中医杂志,2006,33(10)：1288-1289
[95]尤建良.培土生金方配合化学治疗肺癌68例.交通医学,2006,20(5)：530-532
[96]蔡红兵,代方国,阂清芬等.中医药配合放疗治疗非小细胞肺癌的临床研究.第一军医大学学报,2002,22(12)：1112-1115
[97]吴万垠,邓宏.参附注射液对NP方案治疗非小细胞肺癌减毒作用的临床研究.新中医,2006,38(10)： 20-23
[98]方锦明,王维平,阎秉伟等.三生化痰汤在非小细胞肺癌化疗中的应用[J],中西医结合学报,2004,2(2)：103-105
[99]黄希庭.人格心理学(M).杭州：浙江教育出版社.2002：626
[2]Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in brochiogenus carcinoma. A study of six hundred and eighty four proved cases. JAMA 1950; 143:328-336.
[3]Miller BA,Ries LAQHankey BF,et al.(1993)SEER Cancer Statistics Review 1973-1990.Bethesda, MD:NIH Pub.No.93-2789.
[4]Doll R,Gray R,Hafner B,et al.(1980)Mortality in relation to smoking:22 years'observations on female British doctors.Br Med J 1,967-971.
[5]Walter SD,Kubik A,Parkin DM,et al.(1992)The natural history of lung cancer estimated from the result of a randomized trial of screening.Cancer Causes and Control,3,115-123.
[6]Garfinkel L,Stellman SD(1988)Smoking and lung cancer in women:findings in a prospective study. Cancer Res 48,6951-6955.
[7]Kaufman DW,Palmer JR,Rosenberg L,et al.(1989)Tar content of cigarettes in relation to lung cancer.Am J Epidemiol,129,703-711.
[8]Kubik A,ReissigovaJ(1990)Nepriznivyvyvojumrtnosti na plicnirakovinu vCesk6republice.Cas.Lek.ces., 129,217-1223.
[9]Davila DG, Williams DE(1993)The etiology of lung cancer.Mayo Clin.Proc.,68,170-182.
[10]Nilson R(2001)Environmental tobacco smoke revisited:the reliability of the data used for risk assessment.Risk Anal,Aug;21 (4),737-760.
[11]Trichopolous D,Kalandini A,Sparros L,et al.(1984)Passive smoking and lung cancer.Lancet,1,684.
[12]Environmental Protection Agency:Respiratory health effects of passive smoking:lung cancer and other disorders.Washington:Epa,1992.
[13]Samet JM(ed.)Epidemiology of lung cancer.New York:Marcel Dekker,Inc.1994.P.544.
[14]Kabat GC. Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Lung Cancer 1996; 15:1-20.
[15]Du YX, Cha Q, Chen XW, et al. An epidemiological study of risk factors for lung cancer in Guangzhou, China. Lung Cancer 1996; 14:S9-37.
[16]Shen XB, Wang GX, Huang YZ, et al. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer 1996; 14:S107-S112.
[17]Kabat GC, Wynder EL. Lung cancer in nonsmokers. Cancer 1984; 53:1214-1221.
[18]Luh KT, Chang DB. Primary lung cancer in Taiwan. J Formosan Med Assoc 1992; 91:S1-S7.
[19]王志瑾.肺癌流行病学[J]肿瘤防治杂志,2002,9(1)：1-5.
[20]Ko YC,Cheng LS,Lee CH,et al.Chinese food cooking and lung cancer in women nonsmokers[J].Am J Epidemiol,2000,151 (2):140-147.
[21]Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci1979;330:473-490.
[22]Rugo HS. Occupational cancer. In:Current Occupational& Environmental Medicine,4th Ed. LaDou J (ed).NewYork:McGraw-Hill,2007, p224-261.
[23]Samet JM(1989)Radon and lung cancer.J Natl Cancer Inst 81,745-757.
[24]Garfinkel L(1981)Time trends in lung cancer mortality among non-smokers and a note on passive smoking.J Natl Cancer Inst 66,1061-1066.
[25]Field RW,Krewski D,Lubin JH,et al.An overview of the North American residential radon and lungcancer case-control studies.J Toxicol Environ Health A.2006 Apr;69(7):599-631.
[26]Lubin JH,Boice JD(1989)Estimating Rn-induced lung cancer in the United States.Health Phys 57,417-427.
[27]Agudo A, Esteve MG, Pallares C, et al. Vegetable and fruit intake and the risk of lung cancer in women in Barcelona, Spain. Eur J Cancer 1997; 33:1256-1261.
[28]Alavanja MCR, Field RW, Sinha R, et al. Lung cancer risk and red meat consumption among Iowa women. Lung Cancer 2001; 34:37-46.
[29]Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48:7279-7284.
[30]Voorrips LE, Goldbohm RA, Brants HA, et al. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:357-365.
[31]Ko YC, Lee CH, Chen MJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997; 26:24-31.
[32]Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48:7279-7284.
[33]Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001; 22:593-597.
[34]Rajaee-Behbahani N, Schmezer P, Risch A, et al. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer 2001; 95:86-91.
[35]Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61:1354-1357.
[36]Qingyi W, Lie C, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk:a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772.
[37]Cheng L, Spitz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer:a case-control analysis. Carcinogenesis 2000; 21:1527-1530.
[38]Ide F, Iida N, Nakatsuru Y, et al. Mice deficient in the nucleotide excision repair gene XPA have elevated sensitivity to benzo[a]pyrene induction of lung tumors. Carcinogenesis 2000; 21:1263-1265.
[39]Zienolddiny S, Ryberg D, Gazdar AF, et al. DNA mismatch binding in human lung tumor cell lines. Lung Cancer 1999; 26:15-25.
[40]Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987; 40:604-609.
[41]Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44:833-839.
[42]Freedman Da,Navidi WC(1990)Ex-smokers and the multistage model for lung cancer.Epidemiology, 1,21-29.
[43]Bernard W.Stewart,Paul Kleihues,edit.World Cancer Report.IARC Press.Lyon 2003:185.
[44]黄信孚,林木耀主编.现代肿瘤学诊疗手册.北京：北京医科大学中国协和医科大学联合出版社,1995.323.
[45]马文江,周建英,王雪芬等.原发性肺类癌42例临床分析[J].浙江医学,2003,25(7)：415-417.
[46]Waller DA.Surgery for non-small cell lung cancer-new trends.Lung Cancer,2001,34(Suppl 2):S133-136.
[47]李佩文主编.肺癌综合诊疗学.中国中医药出版社,2001：303-304.
[48]刘嘉湘,施志明,徐振华等.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J]中医杂志,1995：36(3)：155-158
[49]李际强.刘伟胜攻毒法治疗肺癌经验简介[J].辽宁中医杂志,2009：36(3)：340-341
[50]郑红刚,花宝金,朴炳奎.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007；26(5)：273-275.
[51]张霆.从伏气学说探讨肺癌之病因病机7J2.中医研究,2007；20(3)：5-7.
[52]赵景芳.七情与癌的发生.江苏中医药,2990,11(11)：42
[53]匡调元.论辨证与辨体质[J].中国中医基础医学杂志,2002,8(2)：1.
[54]匡调元.中医体质病理学[M],上海；上海科学普及出版社,1996
[55]王琦.中医体质学[M].北京：人民卫生出版社,2005：2-85
[56]王琦.中医体质学说的研究现状与展望[J].山东中医学院学报,1994,18(2)：74.
[57]邓海滨,王中奇.徐振哗辨治肺癌经验[J].四川中医,2002；20：1-2.
[58]刘振东,吴林生,周维顺.治疗肺癌经验[J].浙江中医学院学报,2004；28：39-40
[59]马纯正,牛喜伟.中医辨证治疗晚期非小细胞肺癌62例[J].中医杂志,2003,44(8)：6
[60]王维.原发性支气管肺癌的辨证论治[J].中华实用中西医杂志,2005,14(4)：399-401
[61]陈四清,周仲瑛.原发性支气管肺癌辨证分型探讨[J].新中医,2002；34(11)：6-8
[62]贾立群,朱世杰.现代名中医肿瘤科绝技[M].北京：(周岱翰老中医治肺癌经验)科学技术文献出版社,2002
[63]赵炜.李佩文治疗肺癌的经验[J].北京中医杂志,2002,21(6)：329-330
[64]刘静冰.章永红教授辨治肿癌经验探要[J].实用中医内科杂志,2002,16(3)：124-125
[65]曹阳,李忠,辨证治疗晚期非小细胞肺癌31例[J].北京中医药大学学报,2000,23(2)：66
[66]崔同建.中西医结合治疗非小细胞肺癌75例疗效分析[J].福建中医药,2002,33(2)：7-8
[67]陈国荣.中西医结合治疗非小细胞肺癌疗效观察[J].中国中西医结合杂志,1999,19(10)：620-621
[68]王三虎.肺癌急症辨证论治.中国中西医结合急救杂志,2006,13(5)：314
[69]夏黎明,林起铨,吴飞雪等.中医药治疗原发性肺癌临床疗效探析[J].中国中医基础医学杂志,2001,7(8)：52-54
[70]苗文红.中医辨证治疗肺癌89例报告[J].陕西肿瘤医学,2001,9(：1)59
[71]李际强,罗翌,徐凯.刘伟胜教授治疗肺癌经验介绍.新中医,2007,39(3)：99-100
[72]夏绍军.中医药与肿瘤的免疫调节概述[J].中医药临床杂志,2004,16(4)：288-289
[73]刘嘉湘.滋阴生津温阳法治疗晚期原发性肺腺癌的临床观察.中医杂志,1995,3：155-158
[74]李东方,中医辨证治疗晚期非小细胞肺癌32例临床观察[J].四川中医,2003,21(1)：33-34
[75]王永炎.中医内科学.第6版,上海科学技术出版社,1997,94-95
[76]王义明.扶正养阴法在治疗支气管肺癌中的应用[J].辽宁中医杂志,1985,9(8)：25.
[77]韩照予,马显振,张耀勇.穴位注射治疗肝癌介入术后呃逆33例[J].中国中西医结合杂志,2001,21(1)：50
[78]李佩文,张代钊.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995,36(2)：87-88.
[79]扬爱光,王兴双.安肺膏外贴治疗肺癌.中医外治杂志,996,(2)：31
[80]朴柄奎.肺瘤平膏治疗晚期原发性肺癌临床观察[J].中医杂志,1991,32(4)：21.
[81]李勇,徐凯.正气化癌膏治疗癌性疼痛30例疗效观察.新中医,2005,40(9)36-37
[82]孙大兴,裘维焰.肺康方治疗中晚期非小细胞肺癌疗效分析.中医药学报,2002；30(2)：49-50.
[83]张亚声.中药外敷治疗恶性胸水50例[J].中医杂志,1993,34(9)：545.
[84]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验.四川中医,2005,23(7)：5-6
[85]赵镜平.艾迪注射液治疗老年晚期非小细胞肺癌疗效观察.药物与临床,2010,48(2)：49
[86]张肖晗.针药并用治疗肿瘤化疗后骨髓抑制临床观察.中华实用中西医杂志.2007,20(6)：502-503
[87]谭兴超.复方苦参注射液治疗晚期非小细胞肺癌临床观察.当代医学,2010,16(3)：65
[88]刘家祥,韩平,王博文.中药配合化疗肺癌30例疗效观察[J],江西中医,2001,22(10)：25-26
[89]李柳宁,刘伟胜.千金苇茎汤加味在肺癌围放疗期的临床应用.辽宁中医杂志,2006,33(12)：1599
[90]陈乃杰,中医辨证配合化疗治疗晚期非小细胞肺癌41例[J].浙江中西医结合杂志,2000,10(1)：6-7
[91]李斯文.康莱特联合化疗治疗非小细胞肺癌的临床研究.肿瘤杂志,2002,22(1)：84
[92]马建青.康艾注射液对晚期肺癌放疗的协助作用.中国中药杂志,2006,31(18)：1556-1558
[93]郝迎旭,崔惠娟,蔡光蓉,等.扶正增效方对肺癌放射作用的研究[J].中医杂志,1997,38(2)：84-85
[94]崔红梅,毋子亭.健脾益肾法合化疗治疗中晚期肺癌疗效观察.辽宁中医杂志,2006,33(10)：1288-1289
[95]尤建良.培土生金方配合化学治疗肺癌68例.交通医学,2006,20(5)：530-532
[96]蔡红兵,代方国,阂清芬等.中医药配合放疗治疗非小细胞肺癌的临床研究.第一军医大学学报,2002,22(12)：1112-1115
[97]吴万垠,邓宏.参附注射液对NP方案治疗非小细胞肺癌减毒作用的临床研究.新中医,2006,38(10)： 20-23
[98]方锦明,王维平,阎秉伟等.三生化痰汤在非小细胞肺癌化疗中的应用[J],中西医结合学报,2004,2(2)：103-105
[99]黄希庭.人格心理学(M).杭州：浙江教育出版社.2002：626